Dor Chemicals earnings worth the wait

Excluding the effect of the losses incurred in the third quarter from its Treofan investment, Dor's net profit rose 286% to NIS 20.2m. for the 9 months ended Sept. 30, 2005, from NIS 5.2m. in the period last year.

November 15, 2005 07:29
1 minute read.
dor chemicals logo 88

dor chemicals logo 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Dor Chemicals released its earnings for the first time in nine months on Monday as profits jumped four-fold in the first three quarters of 2005 compared to the same period last year. The Haifa-based company was previously prevented from publishing its results because its sale of subsidiary Treofan to the banks in February was not completed until September 30. It was therefore required to include Treofan results in its accounting, which it did not have access to, and was consequently unable to provide its own financial results. Excluding the effect of the losses incurred in the third quarter from its Treofan investment, Dor's net profit rose 286 percent to NIS 20.2 million for the nine months ended September 30, 2005, from NIS 5.2m. in the period last year. Revenues were NIS 241.4m., showing a growth of 20% from last year. "The company is in a good position and had very impressive results," said Rimon Ben Shaoul, Chairman of Dor Chemicals. "The growth has come as a result of a restructure at the company and a decision to focus on our core business." Ben Shaoul added that the rise in oil prices over the year also contributed to profits. The company said, however, that it recorded a loss of NIS 197.1m. on the Treofan deal in the third quarter. Dor Chemicals reduced its stake in troubled Treofan from a controlling 51% to its current stake of 5% as the banks took on EU91m. of Treofan's debt in exchange for 92% shares in the Frankfurt-based company. Dor Chemicals has the option to purchase a further 8.6% in the company within the next four years. Dor Chemicals operates in two divisions - its chemicals unit and its plastics division.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection